Enterol, 250 mg 20 pcs.

Pharmacotherapeutic group: Antidiarrheal.

ATX code: A07FA02

Pharmacological properties:

Pharmacodynamics

em>Saccharomyces boulardii CNCM I-745 is a live non-pathogenic yeast (deposited at the National Collection of Cultures and Microorganisms (CNCM), International Depository, Institut Pasteur, Paris).

The preparation Saccharomyces boulardii is a probiotic and acts in the gastrointestinal tract as an anti-diarrheal microorganism.

The pharmacodynamics of Saccharomyces boulardii have been studied in various models in in and in vivo, as well as in preclinical and clinical studies showing that the drug:

– has antimicrobial action due to its antagonistic effect against pathogenic and conditionally pathogenic microorganisms: Clostridium difficile, Candida albicans, Candida krusei, Candida pseudotropicalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella typhimurium, Yersinia enterocolitica, Escherichia coli, Shigella dysenteriae, Staphylococcus aureus and others, and ytica and Lambliae;

– has an antitoxin effect against bacterial cyto- and enterotoxins;

– – increases intestinal enzymatic function;

– A component of the cell wall of Saccharomyces boulardii mannitol is a substrate for pathogenic strains of Escherichia coli and Salmonella typhimurium<

that causes their adhesion (attachment) to the surface of Saccharomyces boulardii and subsequent excretion from the body;

has a natural resistance to antibiotics.

Pharmacokinetics

Saccharomyces boulardii is not eubiotic, is not part of the microflora of the healthy human body. Saccharomyces boulardii is not absorbed, passes through the digestive tract unchanged, without colonization. The concentration of Saccharomyces boulardii in the intestine is maintained at a constant level during the period of administration of the drug. Saccharomyces boulardii is completely eliminated from the body within 2-5 days after discontinuation of the drug.